Gabapentin
Product Images NDC 50436-4290

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 50436-4290). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (50436 0428 1)

Gabapentin 600 mg tablet packaging label showing information for 90 tablets. The label includes the dosage strength (600 mg) and tablet count, manufacturer details (Alkem Laboratories Ltd., Mumbai, India), storage warnings, and directions for pharmacists to dispense the medication guide with each patient. The label also features multiple instances of the drug name, NDC 50436-0428-1, and placeholders for lot and expiration dates. Packaged by Unit Dose Services, LLC, Dania, FL.*

FDA Label Image

Image Description (50436 4290 1)

Gabapentin 800 mg capsules carton label from Unit Dose Services. The label includes the National Drug Code (NDC) 50436-4290-1, specifies 90 tablets per package, and provides manufacturer details for Alkem Laboratories Ltd. in Mumbai, India. It contains warnings about storage temperature and child safety, along with barcodes and lot/expiration placeholders.*

FDA Label Image

Gabapentin Equation (Gabapentin Equation)

An illustration depicting the formula for calculating creatinine clearance (CLCr), including variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplier of 0.85 for female patients.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over 8 weeks comparing placebo and Gabapentin 3600 mg/day. The x-axis shows weeks from baseline to 8, while the y-axis shows mean pain scores from 0 to 10. The graph indicates a 4-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph depicting mean pain scores over a 7-week period comparing placebo with Gabapentin dosages of 1800 mg/day and 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain score values from 0 to 10. Gabapentin groups show a decreasing trend in pain scores compared to placebo, which remains relatively stable over time.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and Gabapentin (GBP) at different doses. Study 1 shows 12% for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance is noted with p-values less than 0.01 and 0.001.*

FDA Label Image

Gabapentin-fig4 (Gabapentin Fig4)

A scatter plot comparing percentage difference against daily doses (mg) of gabapentin across three studies labeled a, b, and c. The x-axis represents daily dose in mg, ranging from 600 to 1800, and the y-axis shows difference percentage from 2% to 22%. Separate markers represent data points from each study at varying dose levels.*

FDA Label Image

Gabapentin-structure (Gabapentin Structure)

Chemical structure of gabapentin, showing its cyclohexane ring attached to amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.